Coherus Oncology, Inc. — Director's Dealing 2020

Jul 21, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Coherus BioSciences, Inc. (CHRS)
CIK: 0001512762
Period of Report: 2020-07-17

Reporting Person: Anicetti Vincent R (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-17	Common Stock	M	2500	$2.5005	Acquired	51056	Direct
2020-07-17	Common Stock	M	12500	$12.70	Acquired	63556	Direct
2020-07-17	Common Stock	S	15000	$18.2458	Disposed	48556	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-17	Stock Option (Right to Buy)	$2.5005	M	2500	Disposed	2024-06-30	Common Stock (2500)	Direct
2020-07-17	Stock Option (Right to Buy)	$12.70	M	12500	Disposed	2027-08-06	Common Stock (12500)	Direct

Footnotes

F1: Includes 31,250 restricted stock units.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

F3: The transaction was executed in multiple trades in prices ranging from $18.11 to $18.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F4: All of the shares underlying this option are vested and exercisable as of the date hereof.